Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3861-3868

  Myint, Lay ^a   Ariysoshi, Koya ^a   Yan, Hua ^a   Frater, Alexander J ^b   Auwanit, Wattana ^e   Pathipvanith, Panita ^c   Yamada, Kaneo ^d   Matsuda, Masakazu ^a   Chiba, Tomoko ^a   Fujita, Kazunori ^a   McClure, Myra ^b   Weber, Jonathan N ^b   Sugiura, Wataru ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LAMPANG HOSPITAL   (Thailand)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ARTICLE; CODON; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DNA TEMPLATE; DRUG RESISTANCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS DETECTION; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; METHODOLOGY;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; ZIDOVUDINE;

EID: 0036895519     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3861-3868.2002     Document Type: Article

References (33)

1. Boucher, C. A., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
2. Chang, J. G., J.-M. Lu, J.-M. Huang, J.-T. Chen, H.-J. Liu, and C.-P. Chang. 1995. Rapid diagnosis of β-thalassaemia by mutagenically separated polymerase chain reaction (MS-PCR) and its application to prenatal diagnosis. Br. J. Haematol. 91:602-607.
3. Deeks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179:1375-1381.
4. Edelstein, R. E., D. A. Nickerson, V. O. Tobe, L. A. Manns-Arcuino, and L. M. Frenkel. 1998. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J. Clin. Microbiol. 36:569-572.
5. Fontaine, E., C. Lambert, J. Servais, D. Ninove, J.-M. Plesseria, T. Staub, V. Arendt, P. Kirpach, I. Robert, F. Schneider, R. Hemmer, and J.-C. Schmit. 1998. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients. J. Hum. Virol. 1:451-456.
6. Frater, A. J., C. C. Chaput, S. Beddows, J. N. Weber, and M. O. McClure. 2001. Simple detection of point mutations associated with HIV-1 drug resistance. J. Virol. Methods 93:145-156.
7. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:593-594.
8. Hecht, F. M., R. M. Grant, C. J. Petropoulos, B. Dillon, M. A. Chesney, H. Tian, N. S. Hellmann, N. I. Bandrapalli, L. Digilio, B. Branson, and J. O. Kahn. 1998. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N. Engl. J. Med. 30:307-311.
9. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug-resistant testing in adults with HIV infection. JAMA 283:2417-2426.
10. Hooker, D., G. Tachedjian, A. E. Soloman, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70:8010-8018.
11. Kaufmann, G. R., K. Suzuki, P. Cunningham, M. Mukaide, M. Kondo, M. Imai, J. Zaunders, and D. A. Cooper. 2001. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res. Hum. Retrovir. 17:487-497.
12. Kellam, P., C. A. B. Boucher, J. M. G. H. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variant whose genotype confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
13. Koch, N., N. Yahi, P. Colson, J. Fantini, and C. Tamalet. 1999. Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. J. Virol. Methods 80:25-31.
14. Kuritzkes, D. R., D. Shugarts, M. Bakhtiari, D. Poticha, J. Johnson, M. Rubin, T. R. Gingeras, M. Kennedy, and J. J. Eron. 2000. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. J. Acquir. Immune Defic. Syndr. 23:26-34.
15. Kusagawa, S., H. Sato, K. Kato, K. Nohtomi, T. Shiino, C. Samrith, H. B. Leng, T. Phalla, M. B. Heng, and Y. Takebe. 1999. HIV type 1 env subtype E in Cambodia. AIDS Res. Hum. Retrovir. 15:91-94.
16. Kusagawa, S., H. Sato, S. Watanabe, K. Nohtomi, K. Kato, T. Shino, M. Thwe, K. Y. Oo, S. Lwin, R. Mra, B. Kywe, S. Yamazaki, and Y. Takebe. 1998. Genetic and serologic characterization of HIV type 1 prevailing in Myanmar (Burma). AIDS Res. Hum. Retrovir. 10:1379-1385.
17. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine. Science 246:1155-1158.
18. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, B. Conway, E. Connick, M. S. Saag, A. Mwatha, L. Corey, P. H. Keiser, M. Kilby, K. Dawson, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2001. Antiretroviral resistance and response to initial therapy among recently HIV infected subjects in North America. Antivir. Ther. 6 (Suppl. 1):21.
19. Merel, P., I. Pellegrin, I. Garrigue, A. Caumont, M. H. Schrive, V. Birac, P. Bonot, and H. Fleury. 2001. Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA analysis system to conventional gel-based systems for HIV drug resistance analysis. J. Virol. Methods 98:9-16.
20. Motomura, K., S. Kusagawa, K. Kato, K. Nohtomi, H. H. Lwin, K. M. Tun, M. Thwe, K. Y. Oo, S. Lwin, O. Kyaw, M. Zaw, Y. Nagai, and Y. Takebe. 2000. Emergence of new forms of human immunodeficiency virus type 1 intersubtype recombinants in central Myanmar. AIDS Res. Hum. Retrovir. 20:1831-1843.
21. Resch, W., N. Parkin, E. L. Stuelke, T. Watkins, and R. Swanstrom. 2001. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc. Natl. Acad. Sci. USA 98:176-181.
22. Rousseau, M. N., L. Vergne, B. Montes, M. Peeters, J. Reynes, E. Delaporte, and M. Segondy. 2001. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 26:36-43.
23. Rusconi, S., S. La Seta Catamancio, F. Sheridan, and D. Parker. 2000. A genotypic analysis of patients receiving zidovudine with either lamivudine, didanosine or zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184, and 215. J. Clin. Virol. 19:135-142.
24. Rust, S., H. Funke, and G. Assmann. 1993. Mutagenically separated PCR (MS-PCR): A high specific one step procedure for easy mutation detection. Nucleic Acids Res. 21:3623-3629.
25. Ruxrungtham, K., and P. Phanuphak. 2001. Update on HIV/AIDS in Thailand. J. Med. Assoc. Thai. 84(Suppl. 1):S1-S17.
26. Sato, H., Y. Tomita, K. Ebisawa, A. Hachiya, K. Shibamura, T. Shiino, R. Yang, M. Tatsumi, K. Gushi, H. Umeyama, S. Oka, Y. Takebe, and Y. Nagai. 2001. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-aminoacid fragment into the reverse transcriptase. J. Virol. 75:5604-5613.
27. Servais, J., C. Lambert, E. Fontaine, J. M. Plesseria, I. Robert, V. Arendt, T. Staub, F. Schneider, R. Hemmer, G. Burtonboy, and J. C. Schmit. 2001. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J. Clin. Microbiol. 39:454-459.
28. Shaffer, N., R. Chuachoowong, P. A. Mock, C. Bhadrakom, W. Siriwasin, N. L. Young, T. Chotpitayasunondh, S. Chearskul, A. Roongpisuthipong, P. Chinayon, J. Karon, T. D. Mastro, and R. J. Simonds. 1999. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand. Lancet 353:773-780.
29. UNAIDS. 2001. AIDS Epidemic Update. World Health Organization, Geneva, Switzerland.
30. Ungsedhapand, C., E. D. Kroon, S. Suwanagool, K. Ruxrungtham, N. Yimsuan, A. Sonjai, S. Ubolyam, S. Buranapraditkun, S. Tiengrim, N. Pakker, C. Kunanusont, J. M. Lange, D. A. Cooper, and P. Phanuphak. 2001. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J. Acquir. Immune Defic. Syndr. 27:116-123.
31. Van Laethem, K., K. Van Vaerenbergh, J.-C. Schmit, S. Sprecher, P. Hermans, V. De Vroey, R. Schuurman, T. Harrer, M. Witvrouw, E. Van Wijngaerden, L. Styver, M. Van Ranst, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1999. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotype populations. J. Acquir. Immune Defic. Syndr. 22:107-118.
32. Villahermosa, M. L., I. Beck, L. Perez-Alvarez, G. Contreras, L. M. Frenkel, S. Osmanov, E. V. de Parga, E. Delgado, N. Manjon, M. T. Cuevas, M. M. Thomson, L. Medrano, and R. Najera. 2001. Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J. Hum. Virol. 4:238-248.
33. Zollner, B., H.-H. Feucht, L. Weitner, A. Adam, M. Schroter, P. Schafer, and R. Laufs. 2001. Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients. J. Clin. Virol. 21:37-45.